Regulatory Rejection of mRNA Flu Vaccine
regulatory response
investigated
The FDA has declined to initiate a review process for Moderna's mRNA-based influenza vaccine candidate.
This matters because regulatory gatekeeping for novel vaccines can significantly delay technological shifts in public health, underscoring how innovation pace depends not only on science but also on regulatory frameworks and evidentiary standards.